1 / 10

Baseline characteristics and eligibility criteria of participating trials

Explore the impact of LDL cholesterol reduction on major vascular events and cause-specific mortality as reported in the Lancet 2005 study by Cholesterol Treatment Trialists’ Collaborators.

yepa
Télécharger la présentation

Baseline characteristics and eligibility criteria of participating trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  2. Proportional effects on cause-specific mortality per mmol/L LDL cholesterol reduction Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  3. Proportional effects on major vascular events per mmol/L LDL cholesterol reduction Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  4. Relation between proportional reduction in incidence of major coronary events and major vascular events and mean absolute LDL cholesterol reduction at 1 year Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  5. Proportional effects on major vascular events per mmol/L LDL cholesterol reduction by year Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  6. Proportional effects on major coronary events per mmol/L LDL cholesterol reduction subdivided by baseline prognostic factors Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  7. 5-year absolute benefits on particular vascular outcomes per mmol/L LDL cholesterol reduction in participants with and without previous MI or CHD Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  8. Proportional effects on major vascular events per mmol/L LDL cholesterol reduction subdivided by baseline prognostic factors Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  9. Proportional effects on cancer incidence per mmol/L LDL cholesterol reduction by site Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

  10. Proportional effects on cancer incidence per mmol/L LDL cholesterol reduction by year Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78

More Related